Besides the initial boost from Lumara's sales and the $20 million in cost savings AMAG plans to achieve, the company sees Lumara as a platform for growth in the field, partly via M&A. "We believe the Lumara Health transaction will facilitate future product acquisitions in an attractive new therapeutic area and is an excellent strategic fit with our Feraheme market expansion plans," CEO William Heiden said in a statement, adding that the company is looking forward to adding "the talented Makena commercial team" to its mix. Lumara will operate as a separate division within AMAG, possibly to make sure that its recent successes with Makena sales continue.